Early outcomes of active surveillance for localized prostate cancer

BJU International

Volumn 95, Issue 7, 2005, Pages 956-960

  Hardie, Claire ^a   Parker, Chris ^a   Norman, Andrew ^a   Eeles, Ros ^a   Horwich, Alan ^a   Huddart, Robert ^a   Dearnaley, David ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Active surveillance; Outcome; Prostate cancer; Treatment protocol; Watchful waiting

Indexed keywords

GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CLINICAL PROTOCOL; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL PROTOCOLS; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 18544362610     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05446.x     Document Type: Article

References (12)

1. Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst 2002; 94: 958-60
2. Parker CC. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004; 5: 101-6
3. Choo R, DeBoer G, Klotz L et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001; 50: 615-20
4. Choo R, Klotz L, Danjoux C et al. Feasibility study, watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167: 1664-9
5. Carter HB, Walsh PC, Landis P et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002; 167: 1231-4
6. Nicholson PW, Harland SJ. Survival prospects after screen-detection of prostate cancer. BJU Int 2002; 90: 686-93
7. Stamey TA, Kabalin JN, McNeal JE et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076-83
8. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993; 71: 2031-40
9. Parker CC, Dearnaley DP. The management of PSA failure after radical radiotherapy for localized prostate cancer. Radiother Oncol 1998; 49: 103-10
10. Sandler HM, Dunn RL, McLaughlin PW et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 2000; 48: 629-33
11. McLaren DB, McKenzie M, Duncan G et al. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998; 82: 342-8
12. Epstein JI, Walsh PC, Carter HB. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 2001; 166: 1688-91